ISIlya Veniaminovich Schastlivtsev

Ilya Veniaminovich Schastlivtsev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ilya Veniaminovich Schastlivtsev has a total of 117 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Oral rivaroxaban for the treatment of deep vein thrombosis in outpatients: a propensity score-matched comparison with a historical inpatient population

    by Ilya V. Schastlivtsev, Kirill V. Lobastov, Emel Dubar, Athena V. Matveeva, Anna V. Kovalchuk, Sergey N. Tsaplin, Leonid A. Laberko

    Article: Oral rivaroxaban for the treatment of deep vein thrombosis in outpatients: a propensity score-matched comparison with a historical inpatient population - International Angiology 2024 December;43(6):553-62 - Minerva Medica - Journals


  • Positive Predictive Value of the Wells Score in Diagnosis of Deep Vein Thrombosis: Results of Bayesian Analysis

    by I.V. Schastlivtsev, K.V. Lobastov, S.N. Tsaplin, N.N. Burlov, M.S. Kuznetsov, S.V. Zhuravlev, G.V. Rodoman

    Objective. To evaluate the positive predictive value of the Wells score for diagnosis of deep vein thrombosis (DVT) depending on prevalence in population. Material and methods. We retrospectively analyzed the prospectively collected data of all patients who admitted to the Clinical Hospital No. 1 of the Presidential Executive Office with suspected DVT in 2012—2018. Upon admission, we assessed the risk of DVT using Wells score with subsequent Doppler ultrasound. In 2013—2014, an educational program was launched to increase the awareness of physicians about the methods of diagnosis and treatment of venous thromboembolism (VTE). We analyzed positive and negative post-test probability with 89% credible interval for Wells score ≥2 regarding the risk of DVT depending on prevalence using Bayesian analysis. Results. There were 867 patients with suspected DVT (425 (49%) men and 442 (51%) women) aged 19—101 years (mean 62.4±16.3). Of these, 467 (53.9%) ones had Wells score ≥2. DVT was confirmed in 462 (53.3%) cases. Sensitivity and specificity of the Wells score in the entire sample were 92.9% and 90.6%, respectively. In 2012—2013 (before introduction of educational program), the prevalence of DVT was 35.3%, in 2014—2018 — 64.1%. Positive predictive value increased from 9.05% (89% credible interval 7.37—11.24) to 99.47% (89% credible interval 99.34—99.59), negative predictive value — from 0.09% (89% credible interval 0.07—0.11) to 63.03% (89% credible interval 56.84—68.25) with DVT prevalence increase from 1% to 95%. Conclusion. Predictive value of the Wells score depends on population. In case of DVT prevalence > 30%, positive post-test probability of the Wells score exceeds 80%. This justifies anticoagulation before establishing the diagnosis.

  • Phlebolymphedema: Modern Views and Methods of Correction

    by K.V. Lobastov, M.YU. Kaplina (Demekhova), Yu.A. Kononova, V.V. Kozlova, I.V. Schastlivtsev

    Objective. To summarize the available data on the role of lymphatic insufficiency in CVI and its correction using CVD treatment approaches. Material and methods. We reviewed the PubMed and eLibrary databases using the keywords «phlebolymphedema», as well as analyzed available articles. Results. Revising the Starling’s law excluding fluid reabsorption at the venous end of the capillary and placing responsibility for fluid drainage on lymphatic system is important for the concept of phlebolymphedema. Progressive venous hypertension and increased plasma filtration can lead to functional insufficiency and damage to lymphatic system. Available data confirm progressive impairment of lymphatic outflow in parallel with progression of CVD. Modern methods of morphofunctional assessment of superficial lymphatic system, in particular ICG lymphography, allows us to take a new look at pathogenesis of CVI. Standard methods of CVD treatment can have a positive effect on lymphatic outflow, but available data are contradictory. Therapeutic effect of compression therapy is mainly limited to fluid movement through the interstitium towards intact lymphatic vessels. Various drugs including micronized purified flavonoid fraction demonstrate a positive effect on lymphatic drainage. Appropriate therapy is followed by effective relief of venospecific subjective symptoms, chronic edema and trophic disorders. Surgery for superficial and deep veins can improve lymphatic drainage, but clinical results are naturally worse in case of lymphatic insufficiency. Conclusion. Damage to lymphatic system is essential for progressive forms of CVD that emphasizes the need for further study of this issue and development of prevention methods.


  • Open Access

    An updated approach to the risk assessment and prevention of postoperative venous thromboembolism in varicose vein surgery

    by K. V. Lobastov, M. V. Shaldina, D. A. Borsuk, S. V. Kochetkov, I. V. Schastlivtsev, L. A. Laberko, A. A. Fokin

    This narrative literature review is dedicated to the issue of individual risk assessment and prevention of postoperative VTE in patients undergoing lower limb varicose vein surgery. The registry-based CAPSIVS trial showed that the detection frequency of any forms of VTE after modern minimally invasive superficial vein surgery reaches 3.4%, of which only 0.5% are symptomatic. The current clinical guidelines regulate the individual risk assessment of postoperative thrombosis using the Caprini Risk Score (CRS). The first validation study resulted in a proposal of evidence-based approach to the phlebological patient stratification into risk groups according to the Caprini scores with 0–6 scores indicating the low risk, 7–10 scores – the moderate risk and 11 scores or more –the high risk, which differs significantly from approaches in other medical specialties. At the same time, the pharmacoprophylaxis may be appropriate in the groups of moderate and high risk, especially when simultaneous varicose tributary ablation and perforating vein interventions increasing the risk of VTEC 6–11 times are performed. The duration of pharmacoprophylaxis of postoperative venous thrombosis is essential to its efficiency, which should not be less than 7 days for the moderate VTE risk group and reach 30 days for the high VTE risk group. A single injection of parenteral anticoagulants on the day of surgery has been shown to be associated with an 8.8% incidence of postoperative thrombosis. The risk of postoperative thrombosis in patients with VTE in their past medical history, including prior varicothrombophlebitis is increased by 4.2 times, which requires that secondary pharmacoprophylaxis be prescribed for at least 30 days, and in some cases up to 3-6 months. At this stage, there is sufficient evidence to support the use of the Caprini Risk Score to assess the risk of postoperative VTE and prescribe adequate pharmacological prophylaxis in varicose vein surgery treatment.

  • Open Access

    Efficacy and safety of direct oral anticoagulants in patients with implanted inferior vena cava filters: a systematic review and meta-analysis

    by I. V. Schastlivtsev, V. V. Kozlova, A. B. Bargandzhiya, K. V. Lobastov

    Nowadays, vitamin K antagonists (VKA) remain the anticoagulants of choice for patients with implanted inferior vena cava (IVC) filters, while the use of direct oral anticoagulants (DOACs) is controversial. Aim of the review – the study aimed to compare the efficacy and safety of DOACs and VKAs in patients with IVC filters. A systematic search for the relevant papers was performed in Medline (Pubmed) and the Cochrane Library according to the PRISMA guidelines. The inclusion criteria for the analysis were as follows: comparative studies of any design that enrolled patients with verified venous thromboembolism (VTE) who underwent IVC filter implantation and received long-term therapy with DOACs or VKAs with reported numbers of thrombotic and hemorrhagic complications within a follow-up of ≥3 months. The primary endpoints were VTE recurrence and major bleeding. Secondary endpoints included deep vein thrombosis (DVT), IVC thrombosis or filter occlusion, pulmonary embolism (PE), clinically relevant non-major (CRNM) bleeding, any bleeding, and all-cause mortality. Meta-analysis was performed using a random or fixed-effect model depending on the identified heterogeneity. As a result of the literature search was performed in July 2024 and identified 189 references, of which four articles were selected for full-text analysis after screening and excluding 174 irrelevant papers. The final qualitative analysis and quantitative synthesis included two retrospective cohort studies of 302 patients comparing rivaroxaban and warfarin. There were no significant differences between rivaroxaban and warfarin according to the prespecified endpoints. Rivaroxaban is the only DOAC studied in patients with IVC filters. Anticoagulation with rivaroxaban is not less effective and safe than with warfarin after IVC filter implantation.


  • Efficacy and Safety of Different Anticoagulation Regimens for Deep Vein Thrombosis in Real Clinical Practice

    by I.V. Schastlivtsev, K.V. Lobastov, S.N. Tsaplin, A.V. Matveeva, S.V. Zhuravlev, G.V. Rodoman

    OBJECTIVE To evaluate the effectiveness and safety of different anticoagulation regimens for deep vein thrombosis in real clinical practice. MATERIAL AND METHODS We retrospectively analyzed the prospectively collected data on 462 patients with deep vein thrombosis. Patients in the main group received rivaroxaban, in the control group — warfarin. RESULTS The main group included 340 patients (179 men and 161 women aged 26-101 years (mean 61.5±15.6 years), the control group — 122 patients (60 men and 62 women aged 20—93 years (mean 62.0±16.8)). Recurrent venous thromboembolism under anticoagulation occurred in 6 (1.3%; 95% CI 0.6—2.8%) cases (1 (0.3%; 95% CI 0.1—1.7%) and 5 (4.1%; 95% CI 1.8—9.2%) cases, respectively, p=0.006). Bleeding occurred in 49 (10.6%; 95% CI 8.1—13.7%) patients (34 (10.0%; 95% CI 7.2—13.6%) and 15 (12.3%; 95% CI, 7.6—19.3%) patients, respectively, p=0.495). There were 2 (1.6%; 95% CI 0.5—5.8%) major bleeding events under warfarin therapy and no similar events in the main group. The Kaplan-Meier freedom from recurrent thrombosis and major bleeding was significantly in the main group. CONCLUSION Rivaroxaban for the treatment of deep vein thrombosis has made anticoagulation not only effective, but also safe regarding the risk of major bleeding.


  • Open Access

    Oral Rivaroxaban Versus Warfarin After inferior Vena cava Filter Implantation: A Retrospective Cohort Study

    by Ilya Schastlivtsev, Aleksey Pankov, Sergey Tsaplin, Evgeny Stepanov, Sergey Zhuravlev, Kirill Lobastov

    Objectives: To assess the efficacy and safety of rivaroxaban compared to warfarin after inferior vena cava (IVC) filter implantation. Method: This retrospective analysis includes data from 100 patients with deep vein thrombosis (DVT) who underwent IVC filter implantation due to a free-floating thrombus (n = 64), thrombus propagation (n = 8), or acute bleeding (n = 8) on therapeutic anticoagulation, catheter-directed thrombolysis (n = 8), or had previously implanted filter with DVT recurrence. Patients were treated with warfarin (n = 41) or rivaroxaban (n = 59) for 3-12 months. Symptomatic venous thromboembolism (VTE) recurrence and bleeding events were assessed at 12 months follow-up. Results: Three (7.3%) cases of VTE recurrence without IVC filter occlusion occurred on warfarin and none on rivaroxaban. The only (2.4%) major bleeding occurred on warfarin. Three (5.1%) clinically relevant non-major bleedings were detected on rivaroxaban. No significant differences existed between groups when full and propensity scores matched datasets were compared. Conclusions: Rivaroxaban seems not less effective and safe than warfarin after IVC filter implantation.


  • Open Access

    Venous thromboemboliс complications and tuberculosis: is there an interaction?

    by D. V. Plotkin, A. I. Titomer, M. N. Reshetnikov, I. V. Schastlivcev, E. O. Loshkareva, D. A. Ivanova, M. V. Sinitsyn, E. M. Bogorodskaya

    Venous thromboembolic complications (VTEC) haven’t lost their status as an important medical and social problem for many decades. There are about 300 thousand people die from VTEC in Russia every year. Another significant problem for our country is tuberculosis. Tuberculosis is one of the most common severe infections in the world, most often occurs as a chronic disease and can induce VTEC due to a variety of synergistically acting factors. Previously published studies examined the interaction between tuberculosis and VTEC, but they were based on the data obtained from countries with a high incidence of tuberculosis and a low prevalence of venous thrombosis. An analysis of the literature has shown that tuberculous inflammation determines all three interrelated components of the Virchow’s triad: endothelium inflammatory damage, venous stasis and hypercoagulability. In addition, treatment regimens for the disease with the inclusion of rifampicin also contribute to the development of VTEC due to the pronounced procoagulant properties of the drug. Another equally important agent that potentiates hypercoagulation is the HIV virus, which affects the endothelium and immunocompetent cells. Currently available epidemiological data indicate that HIV infection is associated with an increased risk of VTEC in 2-10 times compared to the general population of the same age. In this context, tuberculosis and HIV/TB co-infection can be considered as a large reversible risk factor for the development of VTEC and included in the prognostic risk assessment scales for acute venous thrombosis and embolism.


  • The evolution of the Caprini score

    by K. V. Lobastov, A. V. Kovalchuk, I. V. Schastlivtsev, L. A. Laberko

    The article is a narrative review of the literature that addresses the issues of individual risk assessment of hospital-acquired VTE using the Caprini score. It provides modern epidemiological data confirming the high medical and social significance of the problem of hospital venous thrombosis. The questions of the natural evolution of the Caprini score since the publication of the initial version in 1991 are discussed, a comparative analysis of the modifications of 2005, 2010 and 2013 is carried out, and the features of validation studies that have proven the superiority of the classical version of 2005 are discussed. Attention is paid to the problem of integrating the Caprini score into medical documentation with automation of the process of risk assessment and the appointment of preventive measures. The issue of heterogeneity of approaches to dividing patients into risk groups for developing VTE in accordance with the assessed scores is discussed separately; data from modern studies are presented confirming the existence of very high (9–10 points) and extremely high (≥11 points) risk groups that require an individual approach to prevention of thrombotic complications. Summary data are provided on the frequency of registration of VTE in accordance with Caprini scores in patients of various medical profiles based on a meta-analysis of 68 validation studies. The possibility of using patient-oriented questionnaires based on the Caprini score is discussed, which demonstrate high consistency with the original scale, but have not yet been studied in prospective studies. Revised algorithms are proposed to individually assess the risk of VTE using the 2005 vers of the Caprini score and prescribe adequate prophylaxis. It is concluded that the Caprini score still continues to improve and evolve in accordance with general trends in the development of medicine and healthcare, while maintaining the status of the most studied and in demand system for individual assessment of the risk of developing hospital-acquired VTE.


  • The trends in venous thromboembolism occurrence and prevention after minimally invasive varicose vein surgery

    by Kirill Lobastov, Maria Shaldina, Athena Matveeva, Anna Kovalchuk, Denis Borsuk, Ilya Schastlivtsev, Leonid Laberko, Alexey Fokin

    Objectives: To assess the trends of VTE occurrence and prevention in varicose vein surgery. Method: The registry-based CAPSIVS trial (NCT03041805) analysis includes results in 1878 lower limbs. The primary outcome is a 28-day symptomatic or asymptomatic DVT revealed with duplex ultrasound. Results: Any DVT, including EHIT, was observed in 3.4%, while symptomatic in 0.5%. Prophylactic anticoagulation was administrated in 20.4% with LMWH (13.2%) or DOAC (7.1%) for patients with higher VTE risk but did not reduce the events rate. With propensity score matching DOACs were superior to LMWHs (1.5% vs 9.8%). Duration of anticoagulation was essential: the lowest incidence (4.2%) was associated with prophylaxis for up to 7 days, while a single LMWH injection resulted in a DVT rate of 8.8%. With individual VTE history, any anticoagulation duration appeared insufficient. Conclusions: Prophylactic anticoagulation after varicose vein surgery should be based on the individual VTE risk and provided for ≥7–30 days.